South Korea Govt. Proposes “Refund System” To Give Multinational Pharmas Access To Patients At The Price They Want
This article was originally published in The Pink Sheet Daily
Companies would “donate” difference between their price and the Ministry for Health, Welfare and Family Affairs’ preferred price to the government.
You may also be interested in...
Pfizer is advocating a new U.S. trade stance toward setting parameters around foreign governments' drug reimbursement policies in middle-income nations
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.